Last updated 2 months ago
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
3435 patients around the world
Available in Argentina
Chiesi Farmaceutici S.p.A.
22Research sites
3435Patients around the world
This study is for people with
Chronic obstructive pulmonary disease
Copd
Chronic bronchitis
Requirements for the patient
From 40 Years
All Gender
Medical requirements
Sites
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Centro Respiratorio Quilmes - Buenos Aires
Recruiting
Sala de Primeros Auxilios Alberto Mignaburu - Berazategui, Prov Buenos Aires
Recruiting
Centro de Investigaciones Médicas Mar del Plata SRL
Recruiting
Centro Médico Respire S.R.L. - San Fernando - Buenos Aires
Recruiting
CEPIR - La Plata
Recruiting
Instituto de Medicina Respiratoria IMER - Córdoba
Recruiting
StudyPILASTER
SponsorChiesi Farmaceutici S.p.A.
Study typeInterventional
Conditions
CopdChronic bronchitis
Requirements
From 40 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04636801
